The Journal of Organic Chemistry
Article
size) in 5% ethyl acetate in hexane to yield a yellow, amorphous solid
(61.91 mg, 41% in batch and 130.87 mg, 52% in flow); 1H NMR (400
MHz, CDCl3): δH 7.99−7.97 (m, 1H), 7.84−7.81 (m, 2H), 7.69−
6.67 (m, 2H), 7.54−7.52 (m, 1H), 7.55−7.48 (m, 2H), 7.42 (s, 1H),
7.26−7.20 (m, 4H), 6.18 (s, 1H), 5.01 (s, 2H), 3.83 (s, 3H); 13C{1H}
NMR (100 MHz, CDCl3): δC 169.2, 168.1, 139.3, 136.7, 133.8, 132.3,
132.2, 130.9, 130.6, 127.7, 127.4, 126.4, 123.2, 122.5, 120.6, 120.0,
114.1, 111.5, 109.1, 61.4, 53.0, 31.9; HRMS (ESI-TOF) m/z: [M +
H]+ calcd for C26H20BrN2O4, 503.0601; found, 503.0619.
Hz), 115.5, 110.1, 87.7, 61.7, 51.5; HRMS (ESI-TOF) m/z: [M +
H]+ calcd for C18H14FN2O2, 309.1034; found, 309.1041.
4.2.2.14. Methyl 2-(3-Formyl-1H-indol-1-yl)-2-phenylacetate,
3m. 3m was synthesized using general procedure by reacting 1d
and 2a, and purification was performed by column chromatography in
silica gel (100−200 mesh size) in 10% ethyl acetate in hexane to yield
1
a yellow, amorphous solid (104.13 mg, 71% in flow); H NMR (400
MHz, CDCl3): δH 9.94 (s, 1H), 8.34−8.32 (m, 1H), 7.72 (s, 1H),
7.48−7.46 (m, 3H), 7.41−7.34 (m, 5H), 6.26 (s, 1H), 3.85 (s, 3H);
13C{1H} NMR (100 MHz, CDCl3): δC 185.1, 169.2, 137.7 137.6,
133.0, 129.9, 129.7, 128.5, 125.5, 124.5, 123.6, 122.6, 119.1, 109.5,
62.4, 53.4; HRMS (ESI-TOF) m/z: [M + H]+ calcd for C18H16NO3,
294.1125; found, 294.1116.
4.2.2.9. Methyl 2-(3-((1,3-Dioxoisoindolin-2-yl)methyl)-1H-indol-
1-yl)-2-(4-fluorophenyl)acetate, 3h. 3h was synthesized using
general procedure by reacting 1e and 2e, and purification was
performed by column chromatography in silica gel (100−200 mesh
size) in 5% ethyl acetate in hexane to yield a yellow, amorphous solid
4.2.2.15. Methyl 2-(3-Formyl-1H-indol-1-yl)-2-(3-
methoxyphenyl)acetate, 3n. 3n was synthesized using general
procedure by reacting 1d and 2g, and purification was performed
by column chromatography in silica gel (100−200 mesh size) in 10%
ethyl acetate in hexane to yield an orange-red, amorphous solid
(130.95 mg, 81% in flow); 1H NMR (400 MHz, CDCl3): δH 9.95 (s,
1H), 8.34−8.32 (m, 1H), 7.74 (s, 1H), 7.40−7.32 (m, 4H), 7.00−
7.97 (m, 2H), 6.92 (t, J = 2.2 Hz, 1H), 6.22 (s, 1H), 3.84 (s, 3H),
3.81 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δC 185.3, 169.1,
160.5, 137.7, 137.6, 134.3, 130.8, 125.5, 124.5, 123.6, 122.6, 120.6,
119.1, 115.4, 114.6, 109.5, 62.3, 55.5, 53.4; HRMS (ESI-TOF) m/z:
[M + H]+ calcd for C19H18NO4, 324.1230; found, 324.1242.
4.2.2.16. Methyl 2-(3-Cyano-1H-indol-1-yl)-2-(3-
methoxyphenyl)acetate, 3o. 3o was synthesized using general
procedure by reacting 1c and 2g, and purification was performed
by column chromatography in silica gel (100−200 mesh size) in 10%
ethyl acetate in hexane to yield a yellow, amorphous solid (68.23 mg,
1
(146.01 mg, 66% in flow); H NMR (400 MHz, CDCl3): δH 7.89−
7.86 (m, 1H), 7.72−7.70 (m, 2H), 7.58−7.56 (m, 2H), 7.24−7.22
(m, 1H), 7.18−7.09 (m, 4H), 7.03−6.98 (m, 3H), 6.09 (s, 1H), 4.89
(s, 2H), 3.71 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δC 169.7,
168.1, 163.0 (d, J = 248 Hz), 136.4, 133.8, 132.2, 129.9 (d, J = 8.0
Hz), 127.6, 127.4, 123.2, 122.4, 120.5, 120.0, 116.2 (d, J = 22 Hz),
111.2, 109.1, 61.4, 52.9, 32.5; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C26H20FN2O4, 443.1402; found, 443.1425.
4.2.2.10. Methyl 2-(4-Bromophenyl)-2-(3-((1,3-dioxoisoindolin-2-
yl)methyl)-1H-indol-1-yl)acetate, 3i. 3i was synthesized using
general procedure by reacting 1e and 2f, and purification was
performed by column chromatography in silica gel (100−200 mesh
size) in 5% ethyl acetate in hexane to yield a yellow, amorphous solid
(77.01 mg, 51% in batch and 138.42 mg, 55% in flow); 1H NMR (400
MHz, CDCl3): δH 7.93−7.94 (s, 1H), 7.80−7.78 (m, 2H), 7.66−7.64
(m, 2H), 7.51 (d, J = 8.4 Hz, 2H), 7.35 (s, 1H), 7.22−7.18 (m, 5H),
6.14 (s, 1H), 4.97 (s, 2H), 3.79 (s, 3H); 13C{1H} NMR (100 MHz,
CDCl3): δC 168.3, 133.9, 133.6, 132.4, 133.3, 129.7, 127.8, 127.6,
123.4, 123.3, 122.6, 120.7, 120.2, 109.3, 61.7, 53.1, 32.7; HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C26H20BrN2O4, 503.0601; found,
503.0613.
1
71% in batch and 120.13 mg, 75% in flow); H NMR (400 MHz,
CDCl3): δH 7.78−7.76 (m, 1H), 7.62 (s, 1H), 7.41−7.28 (m, 4H),
7.01−6.92 (m, 2H), 6.89−6.88 (m, 1H), 6.19 (s, 1H), 3.83 (s, 3H);
3.81 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δC 168.9, 160.5,
135.8, 134.4, 134.2, 130.8, 127.9, 124.4, 122.8, 120.4, 120.3, 115.1,
114.5, 110.1, 87.4, 62.4, 55.5, 53.4; HRMS (ESI-TOF) m/z: [M +
H]+ calcd for C19H17N2O3, 321.1234; found, 321.1250.
4.2.2.17. Methyl 2-(4-Chlorophenyl)-2-(3-formyl-1H-indol-1-yl)-
acetate, 3p. 3p was synthesized using general procedure by reacting
1d and 2c, and purification was performed by column chromatog-
raphy in silica gel (100−200 mesh size) in 10% ethyl acetate in
hexane to yield an orange, amorphous solid (67.85 mg, 69% in batch
and 117.99 mg, 72% in flow); 1H NMR (400 MHz, CDCl3): δH 9.97
(s, 1H), 8.35−8.32 (m, 1H), 7.74 (s, 1H), 7.44 (d, J = 8.4 Hz, 2H),
7.37−7.32 (m, 5H), 6.23 (s, 1H), 3.85 (s, 3H); 13C{1H} NMR (100
MHz, CDCl3): δC 185.1, 168.8, 137.6, 137.4, 136.1, 131.6, 129.9,
129.7, 125.4, 124.6, 123.7, 122.7, 119.3, 109.5, 61.7, 53.4; HRMS
(ESI-TOF) m/z: [M + H]+ calcd for C18H15ClNO3 328.0735; found,
328.0728.
4.2.2.11. Ethyl 2-(3-((1,3-Dioxoisoindolin-2-yl)methyl)-1H-indol-
1-yl)-2-(p-tolyl)acetate, 3j. 3j was synthesized using general
procedure by reacting 1e and 2b, and purification was performed
by column chromatography in silica gel (100−200 mesh size) in 5%
ethyl acetate in hexane to yield an orange, amorphous solid (106.34
1
mg, 47% in flow); H NMR (400 MHz, CDCl3): δH 7.90−7.87 (m,
1H), 7.74−7.71 (m, 2H), 7.59−7.57 (m, 2H), 7.23−7.09 (m, 8H),
6.07 (s, 1H), 4.90 (s, 2H), 4.24−4.13 (m, 2H), 2.31 (s, 3H), 1.18 (t, J
= 7.2 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δC 169.7, 168.2,
139.1, 139.7, 133.8, 132.4, 131.4, 129.9, 128.2, 128.0, 127.6, 123.2,
122.3, 120.4, 120.1, 110.9, 109.3, 62.13, 62.1, 32.8, 21.3, 14.2; HRMS
(ESI-TOF) m/z: [M + H]+ calcd for [M + H]+ C28H25N2O4
453.1809; found, 453.1828.
4.2.2.12. Methyl 2-(4-Fluorophenyl)-2-(3-formyl-1H-indol-1-yl)-
acetate, 3k. 3k was synthesized using general procedure by reacting
1d and 2c, and purification was performed by column chromatog-
raphy in silica gel (100−200 mesh size) in 10% ethyl acetate in
hexane to yield an orange, amorphous solid (65.38 mg, 70% in batch
and 118.30 mg, 76% in flow); 1H NMR (400 MHz, CDCl3): δH 9.96
(s, 1H), 8.35−8.32 (m, 1H), 7.72 (s, 1H), 7.41−7.34 (m, 5H), 7.18−
7.14 (m, 2H), 6.24 (s, 1H), 3.85 (s, 3H); 13C{1H} NMR (100 MHz,
CDCl3): δC 185.1, 169.1, 163.5 (d, J = 248.9 Hz), 137.5 (d, J = 20.8
Hz) 130.4 (d, J = 8.4 Hz), 129.0, 128.9, 125.5, 124.6, 123.7, 122.6,
119.3, 116.8 (d, J = 21.8 Hz), 109.5, 61.7, 53.5; HRMS (ESI-TOF)
m/z: [M + H]+ calcd for C18H15FNO3, 312.103; found, 312.1027.
4.2.2.13. Methyl 2-(3-Cyano-1H-indol-1-yl)-2-(4-fluorophenyl)-
acetate, 3l. 3l was synthesized using general procedure by reacting
1c and 2e, and purification was performed by column chromatog-
raphy in silica gel (100−200 mesh size) in 10% ethyl acetate in
hexane to yield an off white, amorphous solid (109.45 mg, 71% in
flow); 1H NMR (400 MHz, CDCl3): δH 7.78−7.76 (m, 1H), 7.60 (s,
1H), 740−7.31 (m, 5H), 7.18−7.13 (m, 2H), 7.23 (s, 1H), 3.84 (s,
3H); 13C{1H} NMR (100 MHz, CDCl3): δC 168.9, 163.5 (d, J =
249.0 Hz), 135.7, 134.0, 130.3 (d, J = 8.5 Hz), 128.8 (d, J = 3.8 Hz),
128.5 (d, J = 8.5 Hz), 127.9, 124.5, 122.9, 120.4, 116.8 (d, J = 21.9
4.2.2.18. Methyl 2-(4-Chlorophenyl)-2-(3-cyano-1H-indol-1-yl)-
acetate, 3q. 3q was synthesized using general procedure by reacting
1c and 2c, and purification was performed by column chromatog-
raphy in silica gel (100−200 mesh size) in 10% ethyl acetate in
hexane to yield an orange, amorphous solid (121.79 mg, 75% in flow);
1H NMR (400 MHz, CDCl3): δH 7.78−7.76 (m, 1H), 7.63 (s, 1H),
7.44−7.41 (m, 2H), 7.37−7.32 (m, 3H), 7.29−7.28 (m, 2H), 6.22 (s,
1H), 3.84 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δC 168.6,
136.2, 135.7, 134.0, 131.5, 129.9, 129.6, 128.9, 128.0, 127.8, 124.5,
122.9, 120.4, 115.5, 110.1, 87.8, 61.7, 51.5; HRMS (ESI-TOF) m/z:
[M + H]+ calcd for C18H14ClN2O2, 325.0738; found, 325.0725.
4.2.2.19. Methyl 2-(3-Fluorophenyl)-2-(1H-indol-1-yl)acetate, 3r.
3r was synthesized using general procedure by reacting 1a and 2h,
and purification was performed by column chromatography in silica
gel (100−200 mesh size) in 5% ethyl acetate in hexane to yield an
orange, amorphous solid (45.89 mg, 54% in batch and 80.74 mg, 57%
1
in flow); H NMR (400 MHz, CDCl3): δH 7.65 (d, J = 8.0, 1H),
7.36−7.31 (m, 2H), 7.25−7.21 (m, 1H), 7.19−7.13 (m, 2H), 7.10−
7.03 (m, 3H), 6.57 (d, J = 3.2 Hz, 1H), 6.26 (s, 1H), 3.85 (s, 3H);
13C{1H} NMR (100 MHz, CDCl3): δC 169.7, 163.1 (d, J = 246.1
Hz), 137.3, 136.5, 130.8 (d, J = 8.2 Hz), 128.9, 126.7, 123.7 (d, J =
2530
J. Org. Chem. 2021, 86, 2522−2533